Date: 2011-03-15
Type of information: Results
phase: 1
Announcement: results
Company: Adocia (France)
Product: HinsBet® (fast-acting human insulin)
Action
mechanism: rapid-acting insulin. rapid-acting insulin HinsBet® is a new formulation combining human insulin and a polymer of the BioChaperone® platform. This new family of polymers, “bioinspired” by heparin, has the property to protect and increase the efficacy of therapeutic proteins, with which they form specific molecular complexes. Various BioChaperone® have been tailored made for several proteins (monoclonal antibodies, growth factors as PDGF-BB and BMP).
Disease: type 1 diabetes
Therapeutic area: Metabolic diseases
Country: France
Trial
details: Adocia has announced positive phase I results with its rapid-acting insulin, HinsBet®, for diabetes. Hinsbet® has been compared to NovoLog®, a rapid-acting insulin aspart, and to the classical human insulin Actrapid®, both from Novo Nordisk.
Twelve healthy volunteers have taken part to this double-blind, randomized trial. On the main criterion of the safety, HinsBet® showed results identical to the two tested commercial products, with an excellent local tolerance and an absence of pain in the site of injection. The start of the hypoglycemic action after HinsBet® injection was as short as after NovoLog® injection and shorter than after Actrapid® injection.
Latest
news: Adocia is now preparing a phase IIa study to confirm the fast action and the reduction of variability with Hinsbet® compared to NovoLog®. On the basis of these first results, Adocia aims to conclude a partnership with a company involved in diabetes.
